Establishment of a national travel medicine vaccination network to assess reactogenicity of new and rarely used vaccines: a TropNet study.

The article discusses the establishment of a national travel medicine vaccination network in Germany to monitor the reactogenicity of the newly approved Qdenga® vaccine for dengue. Travel medicine specialists were invited to participate in the network, with 99 out of 1238 contacted specialists joining. The network collected data on vaccine tolerability and side effects, with the majority of participants finding the registration process easy and expressing willingness to participate in future activities. The platform aims to provide unbiased data on novel vaccines to facilitate their integration into clinical practice. [Extracted from the article]